BioWorld

Oct. 11, 2005

PIPE To Give La Jolla $66M For Additional Riquent Study

A stock and warrant sale is providing a much needed shot in the arm to La Jolla Pharmaceutical Co., which is raising $66 million in gross proceeds to hopefully get Riquent (abetimus) across the finish line. (BioWorld Today) Read More

Somaxon IPO Bid Seeking $86.25M For Silenor, More

Welsh Bioscience On The Map And Producing Growing Interest

Vasogen Adds $40M Through Notes Sale For Celacade Work

Holiday notice

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 3, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 3, 2025.

AI-generated illustration of CAR T cells

Researchers arm CAR T cells to fight solid tumors

BioWorld

Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the...

Bioversys, Shionogi in CHF529M lung infection collaboration

BioWorld Science

Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on...

Medtronic receives CE mark for its Vitalflow ECMO system

BioWorld MedTech

Medtronic plc received a CE mark for its Vitalflow extracorporeal membrane oxygenation (ECMO) system, which provides temporary support for the heart and lungs in...